- Home
- RPTX vs ZURA Comparison
RPTX vs ZURA Comparison
Compare RPTX & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- ZURA
- Stock Information
- Founded
- RPTX 2016
- ZURA 2022
- Country
- RPTX Canada
- ZURA United States
- Employees
- RPTX N/A
- ZURA N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RPTX Health Care
- ZURA Health Care
- Exchange
- RPTX Nasdaq
- ZURA Nasdaq
- Market Cap
- RPTX 63.9M
- ZURA 69.9M
- IPO Year
- RPTX 2020
- ZURA N/A
- Fundamental
- Price
- RPTX $1.56
- ZURA $1.64
- Analyst Decision
- RPTX Strong Buy
- ZURA Buy
- Analyst Count
- RPTX 3
- ZURA 7
- Target Price
- RPTX $4.50
- ZURA $14.33
- AVG Volume (30 Days)
- RPTX 717.8K
- ZURA 1.3M
- Earning Date
- RPTX 08-05-2025
- ZURA 08-08-2025
- Dividend Yield
- RPTX N/A
- ZURA N/A
- EPS Growth
- RPTX N/A
- ZURA N/A
- EPS
- RPTX N/A
- ZURA N/A
- Revenue
- RPTX $1,073,000.00
- ZURA N/A
- Revenue This Year
- RPTX N/A
- ZURA N/A
- Revenue Next Year
- RPTX N/A
- ZURA N/A
- P/E Ratio
- RPTX N/A
- ZURA N/A
- Revenue Growth
- RPTX N/A
- ZURA N/A
- 52 Week Low
- RPTX $0.89
- ZURA $0.97
- 52 Week High
- RPTX $4.22
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- RPTX 58.19
- ZURA 61.26
- Support Level
- RPTX $1.37
- ZURA $1.60
- Resistance Level
- RPTX $1.68
- ZURA $1.79
- Average True Range (ATR)
- RPTX 0.08
- ZURA 0.18
- MACD
- RPTX 0.00
- ZURA 0.03
- Stochastic Oscillator
- RPTX 61.29
- ZURA 50.91
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.